Abstract
Bipolar affective disorder (BD) is a severe, recurrent and disabling disorder with devastating consequences for individuals, families and society. Although these hazards and costs provide a compelling rationale for development of early detection and early intervention strategies in BD, the development of at-risk criteria for first episode mania is still in an early stage of development. In this paper we review the literature with respect to the clinical, neuroantomical and neuropsychological data, which support this goal. We also describe our recently developed bipolar at-risk criteria (BAR). This criteria comprises the peak age range of the first onset of bipolar disorder, genetic risk, presenting with sub-threshold mania, cyclothymic features or depressive symptoms. An initial pilot evaluation of the BAR criteria in 22 subjects indicated conversion rates to proxies of first-episode mania of 23% within 265 days on average, and high specificity and sensitivity of the criteria. If prospective studies confirm the validity of the BAR criteria, then the criteria would have the potential to open up new avenues of research for indicated prevention in BD and might therefore offer opportunities to ameliorate the severity of, or even prevent BD.
Keywords: Bipolar disorder, at-risk criteria, prodrome, conversion, prediction, mania, depression, neuroprogression, psychosis, hallucinations
Current Pharmaceutical Design
Title: Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder
Volume: 18 Issue: 4
Author(s): A. Bechdolf, A. Ratheesh, S. J. Wood, T. Tecic, P. Conus, B. Nelson, S. M. Cotton, A. M. Chanen, G. P. Amminger, S. Ruhrmann, F. Schultze-Lutter, J. Klosterkotter, P. Fusar Poli, A. R. Yung, M. Berk and P. D. McGorry
Affiliation:
Keywords: Bipolar disorder, at-risk criteria, prodrome, conversion, prediction, mania, depression, neuroprogression, psychosis, hallucinations
Abstract: Bipolar affective disorder (BD) is a severe, recurrent and disabling disorder with devastating consequences for individuals, families and society. Although these hazards and costs provide a compelling rationale for development of early detection and early intervention strategies in BD, the development of at-risk criteria for first episode mania is still in an early stage of development. In this paper we review the literature with respect to the clinical, neuroantomical and neuropsychological data, which support this goal. We also describe our recently developed bipolar at-risk criteria (BAR). This criteria comprises the peak age range of the first onset of bipolar disorder, genetic risk, presenting with sub-threshold mania, cyclothymic features or depressive symptoms. An initial pilot evaluation of the BAR criteria in 22 subjects indicated conversion rates to proxies of first-episode mania of 23% within 265 days on average, and high specificity and sensitivity of the criteria. If prospective studies confirm the validity of the BAR criteria, then the criteria would have the potential to open up new avenues of research for indicated prevention in BD and might therefore offer opportunities to ameliorate the severity of, or even prevent BD.
Export Options
About this article
Cite this article as:
Bechdolf A., Ratheesh A., J. Wood S., Tecic T., Conus P., Nelson B., M. Cotton S., M. Chanen A., P. Amminger G., Ruhrmann S., Schultze-Lutter F., Klosterkotter J., Fusar Poli P., R. Yung A., Berk M. and D. McGorry P., Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316226
DOI https://dx.doi.org/10.2174/138161212799316226 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnostic Approach to Mitochondrial Disorders: the Need for a Reliable Biomarker
Current Molecular Medicine Energy Metabolism in the Normal and in the Diabetic Heart
Current Pharmaceutical Design The Mechanism of Carvedilol in Experimental Viral Myocarditis
Current Pharmaceutical Design Consequences of Type 1 and 2 Diabetes Mellitus on the Cardiovascular Regulation During Exercise: A Brief Review
Current Diabetes Reviews Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Involvement of Cytokines and Inflammation in Catecholamine-Induced Pulmonary Injury in Rats
Vascular Disease Prevention (Discontinued) Insulin Therapy in Cardiac Surgery
Current Diabetes Reviews Biomarkers of Subclinical Atherosclerosis and Natural Products as Complementary Alternative Medicine
Current Pharmaceutical Design Inflammatory Biomarkers in Chronic Kidney Disease: A Review
Recent Patents on Biomarkers The Metabolic Approach in Patients with Heart Failure: Effects on Left Ventricle Remodeling
Current Pharmaceutical Design Role of Genetic Factors in the Pathogenesis of Radial Deficiencies in Humans
Current Genomics Transcatheter Aortic Valve Technology: Current State
Recent Patents on Biomedical Engineering (Discontinued) Safety of Dabigatran in an Elderly Population: Single Center Experience in Italy
Current Drug Safety Updated Role of Nitric Oxide in Disorders of Erythrocyte Function
Cardiovascular & Hematological Disorders-Drug Targets Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design Efficacy and Cardiovascular Safety of Thiazolidinediones
Current Drug Safety Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets Chest Pain, Panic Disorder and Coronary Artery Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Pre-CKD- Do we Need Another Hero?
Current Vascular Pharmacology Protein Interaction Studies for Understanding the Tremor Pathway in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets